Roche’s OCREVUS ZUNOVO Gets FDA Approval To Treat Relapsing And Progressive Multiple Sclerosis
(RTTNews) – Swiss drug major Roche (RHHBY) announced Monday that the United States Food and Drug Administration has approved OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis or RMS and primary progressive multiple sclerosis or PP